Skip to main content
Fig. 1 | Health and Quality of Life Outcomes

Fig. 1

From: Patient-reported outcomes and daily activity assessed with a digital wearable device in patients with paroxysmal nocturnal hemoglobinuria treated with ravulizumab: REVEAL, a prospective, observational study

Fig. 1

Summary of PRO measures in patients with PNH treated with ravulizumab compared with the US general population. FACIT Functional Assessment of Chronic Illness Therapy, F females, M males, PRO patient-reported outcome, PROMIS Patient-Reported Outcomes Measurement Information System, WPAI‑SHP Work Productivity and Activity Impairment Questionnaire – Specific Health Problem. Values were collected longitudinally for each participant and estimated marginal means across multiple observations per participant are shown; error bars represent standard deviation. Population normative values are 43.7 (females) and 44.7 (males) for FACIT – Fatigue [27], 48.5 for PROMIS Global Mental Health Short Form (subpopulation norm for age category 18–34 years), 51.6 for PROMIS Global Physical Health Short Form (subpopulation norm for age category 18–34 years), 50.0 for PROMIS sleep measures [28], and 17.0 for WPAI [29]. aFive patients in the ravulizumab group were not working

Back to article page

Health and Quality of Life Outcomes

ISSN: 1477-7525

Contact us